<DOC>
	<DOCNO>NCT00228020</DOCNO>
	<brief_summary>The aim study assess safety efficacy treatment regimen basiliximab , cyclosporine microemulsion , MMF , prednisone combine compare cyclosporine microemulsion , MMF prednisone time first biopsy proven acute rejection episode treatment failure first 6 month post-transplantation pediatric renal allograft recipient .</brief_summary>
	<brief_title>Study Safety Efficacy Basiliximab , Mycophenolate Mofetil , Cyclosporine Microemulsion Prednisone Combination Treatment Regimen Pediatric Renal Allograft Recipients</brief_title>
	<detailed_description />
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients recipient primary secondary renal allograft . Patients singleorgan recipient ( kidney ) . â€¢Patients recipients HLAidentical renal transplant . Patients whose donor kidney cold ischemia time ( CIT ) great 36 hour . Patients whose transplant kidney obtain nonheart beat donor Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>pediatric , kidney transplantation , basiliximab</keyword>
</DOC>